Market Signals: How a USD 4.3B Pact and AI Capex Reshape Sector ExpectationsGlobal Report·12 hours agoWPM+1.32%TTI-2.58%
The Biotech Survival Charade: Stop Buying the "AI Pivot" HypeGlobal Report·12 hours agoINM-7.57%ONCY-4.26%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·1 day ago, 04:17 AMGENB-3.11%IBRX-4.05%
Sector Watch: Wix's AI Overhaul and Crypto Pivots in Small-Cap SpaceGlobal Report·1 day ago, 04:13 AMCLDI-4.76%MASK+1.97%
The AI Spillover: How the Market's Edges are Rewiring Real InfrastructureGlobal Report·2 days ago, 04:13 AMDXST+1.79%BRIA-3.76%
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value DriversUnusual Whales·Jul 21 at 07:10 AMCLDI-4.76%
Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to boardPUBT·Jul 21 at 07:03 AMCLDI-4.76%BMY+0.94%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Jul 20 at 04:05 PMMBAI-5.98%CPHI-17.84%
Calidi Biotherapeutics announces 1-for-16 reverse stock split effective July 31PUBT·Jul 20 at 03:30 PMCLDI-4.76%
Calidi Biotherapeutics Plans Relocation Through New Lease AgreementsTip Ranks·Jul 17 at 03:50 AMCLDI-4.76%
Calidi Biotherapeutics grants VP Finance inducement option for 100,000 shares at $0.15 exercise pricePUBT·Jul 8 at 03:07 PMCLDI-4.76%
Calidi Biotherapeutics director Corazon “Corsee” Sanders files initial beneficial ownership statementPUBT·Jun 29 at 04:13 PMCLDI-4.76%
Calidi Biotherapeutics presents new preclinical data on TROP2-targeting CLD-501 at T-cell engager summitPUBT·Jun 24 at 07:00 AMCLDI-4.76%
